Pharma BD Deal Intelligence

Rani Therapeutics Holdings, Inc. / ProGen Co., Ltd.

2024 · Co-Development · Complete

Rani Therapeutics and ProGen entered a definitive co-development and commercialization agreement for RT-114, which combines ProGen's PG-102 GLP-1/GLP-2 dual agonist with Rani's RaniPill oral biologics delivery capsule for obesity. There is no upfront payment; the parties will share costs and revenues 50/50, with Rani holding US, European, Canadian and Australian rights and ProGen the rest of the world, and a Phase 1 study expected to start in 2025.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2029 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2024 deals